The Japanese pharmaceutical company Kyowa Kirin Co. plans to sell shares in the Chinese division of the Hong Kong company WinHealth Pharma Group Co. for 15 billion yen ($100 million) as part of the ...

Under the deal, Kyowa Kirin will pay BridgeBio $100M upfront, plus royalties up to a high-20s percentage on sales of the product in Japan and potential milestone payments. Kyowa Kirin will develop ...

The deal gives Amgen rights to the KHK4083 antibody in all countries except Kyowa's home market of Japan, and is back-loaded with potential milestone payments worth another $850 million plus ...

Kyowa Kirin ploughed ahead with KW-6356 despite the reservations of its former partner Lundbeck, which held the rights to KW-6356 outside Asia before handing them back to the Japanese company.

Kura Oncology (NASDAQ:KURA) stock slid 17% post-market after the company announced a collaboration deal with Japan's Kyowa Kirin (OTCPK:KNBWY) for its leukemia drug candidate ziftomenib worth up ...